CD274 and cancer: In the durvalumab monotherapy cohort in this study, ORR was numerically higher for all cancer types in patients with PD‐L1 expression using both PD‐L1 cutoffs (TC ≥ 25% and TC ≥ 1%) than in patients with PD‐L1 low or no expression (TC < 25% or TC < 1%), with the exception of BTC, which showed a higher ORR using the PD‐L1 cutoff of TC ≥ 25% but not with TC ≥ 1%.